MedTrace Logo

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

NCT06313970 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2025-09-03

No results posted yet for this study

Summary

This is a multicenter, open-label, exploratory study to evaluate the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine with or without bevacizumab as first-line treatment in patients with unresectable locally advanced or metastatic pancreatic cancer

Conditions

Interventions

DRUG

QL1706

QL1706 5mg/kg，IV，D1, Q3W

DRUG

Nab-paclitaxel

Nab-paclitaxel, 125mg/m2，IV，D1、8, Q3W

DRUG

Gemcitabine

gemcitabine，1000mg/m2，IV，D1、8；Q3W.

DRUG

Bevacizumab

bevacizumab, 7.5mg/kg，IV，D1；Q3W.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-20
Primary Completion
2025-10-31
Completion
2026-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06313970 on ClinicalTrials.gov